Neoleukin Therapeutics (NLTX) Prices 3.26M Share Common Offering at $15.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
After-Hours Stock Movers 7/1: (VERO) (NUS) (FORM) Higher; (CULP) (ZOM) (BLFS) Lower (more...)
July 1, 2020 5:29 PM EDTToday's After-Hours Stock Movers
Venus Concept (NASDAQ: VERO) 56.2% HIGHER; today announced that it has received FDA 510(k) clearance to market and sell Venus Viva MD. Venus Viva MD is a non-invasive device intended to be used by aesthetic-related physicians or dermatologists. It expands the Companys skin rejuvenation offerings beyond the Venus Viva and Venus Versa which were introduced to the medical aesthetics market in 2015 and 2016, respectively.
Culp, Inc. (NYSE: CULP) 19.2% LOWER; reported Q3 EPS of ($2.26), versus ($0.12) reported last... More
Neoleukin Therapeutics (NLTX) Announces 5M Share Proposed Public Offering
July 1, 2020 4:02 PM EDTNeoleukin Therapeutics, Inc. (Neoleukin) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to 5.0 million shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its... More
